sons taking antipsychotic medications, in a yearlong period. Overall, 30.1% of individuals were screened. It would be fair to point out that the efficacy of screening for diabetes has not been well established. However, that less than one-third had such screening for a known adverse effect of antipsychotic medication use suggests opportunities for improvement in integrated health care. Among those who had at least 1 primary care visit during the year, the proportion screened was significantly higher at 35.6% vs 19.8% for those who had no primary care visit.
To improve care for persons with serious mental illness, it will be necessary to break down the silos that separate the mental health and physical health care systems. Integrated care (care provided by a team of physical and mental health clinicians)-or at least colocated care (care provided by physical and mental health clinicians in the same place)-offers the promise of improving the physical health of individuals with mental illness, as well as the mental health of those seeking physical health services.
Mitchell H. Katz, MD
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LESS IS MORE

Use of Intra-aortic Balloon Pump in a Japanese Multicenter Percutaneous Coronary Intervention Registry
We read with interest the recent meta-analysis by Ahmad et al, 1 demonstrating a negative association between intraaortic balloon pump (IABP) therapy and mortality among patients experiencing acute m y o c a r d i a l i n f a r c t i o n . We agree that efforts are needed to clarify the role of IABP therapy and to examine its effect on care in other regions and countries. In Japan, IABP therapy is frequently used in patients with guideline-based indications and in patients with less established indications, and the judicious use of invasive procedures has been highlighted. Results | Baseline demographics in patients with and without IABPs are summarized in the Table. Overall, PCIs after STsegment elevation myocardial infarctions and PCIs after non-ST-segment elevation myocardial infarctions or unstable angina accounted for 23.9% and 24.2% of the procedures, respectively. Before PCI, 486 patients (3.7%) and 900 patients (6.8%) manifested complications of cardiogenic shock and serious heart failure (New York Heart Association functional classification ≥3), respectively. The proportions of interventions for left main trunk and 3-vessel disease were 3.7% and 0.9%, respectively. Intra-aortic balloon pumps were inserted in 885 patients (6.7%). There were 134 in-hospital deaths (15.1%) among the patients receiving an IABP and 111 inhospital deaths (0.9%) among the patients not receiving an IABP. In the crude analysis, the use of IABP was associated with an increased risk of in-hospital mortality ( Figure, A) . Intra-aortic balloon pump use remained an independent predictor of in-hospital mortality after adjusting for baseline differences (odds ratio, 3.87; 95% CI, 2.71-5.52; P < .001). Among several subgroups thought to potentially have indications for IABP use, the use of IABPs was consistently associated with risk of in-hospital death (Figure, B) , and IABP recipients had a worse baseline risk profile than nonrecipients ( Figure, C) . Notably, the risk of death appeared to be higher (with higher odds ratios) as the indications for IABP use became less established.
Discussion | Among a cohort of Japanese patients undergoing PCI in whom IABP use was frequent, we found that the use of IABP was associated with a higher risk of in-hospital death. This Figure. 
IABP Lower Risk Control Lower Risk
A and B, Intra-aortic balloon pump use was adversely associated with patient outcome, regardless of situation, in crude (A) and multivariable (B) analyses. In the logistic regression model, adjustments were made using all variables exhibiting a bivariate association with the use of IABP with P < .001 in the Table, which included all variables except the following: diabetes mellitus, previous coronary artery bypass graft, chronic lung disease, stable angina or silent ischemia, and 1-vessel disease. C, For evaluating the baseline inequality index, we redefined a list of the following baseline characteristics that are recognized markers of mortality risk: age, cardiogenic shock, prior heart failure, peripheral vascular disease, chronic lung disease, renal dysfunction, NYHA functional classification of at least 3 at the time of percutaneous coronary intervention, and clinical presentation (STEMI or NSTEMI). LMT indicates left main trunk; NSTEMI, non-ST-segment elevation myocardial infarction; NYHA, New York Heart Association; and STEMI, ST-segment elevation myocardial infarction. Why is there reluctance to abandon these invasive, expensive, and seemingly ineffective therapies? The answer might be multifactorial. Cardiogenic shock complicating myocardial infarction remains a formidable foe and is associated with 40% to 50% in-hospital mortality. 9 In this setting, only early revascularization has shown improved survival. In some of these critically ill patients, it may seem reasonable to use mechanical circulatory support devices as salvage therapy. However, they offer little benefit in reducing clinical events, and have high costs and significant complication rates. Inohara et al 2 confirm previous findings that IABPs and PVADs are being increasingly used in patients without indications for their use. Although the precise reasons for such excessive use remain to be established, misaligned financial incentives might have a role. Furthermore, continued use of IABPs may be due to established routines or treatment protocols, with commission bias tending toward action rather than inaction.
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Based on available data, the use of these invasive and expensive mechanical circulatory support devices should be critically appraised and limited because of significant complication rates associated with their use and a lack of evidence demonstrating any benefit. In the use of IABPs and PVADs, it seems appropriate to conclude that perhaps less is more.
